Atrovastatin and Ezetimibe combination therapy — Competitive Intelligence Brief

Atrovastatin and Ezetimibe combination therapy (Atrovastatin and Ezetimibe combination therapy) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HMG-CoA reductase inhibitor and cholesterol absorption inhibitor. Area: Cardiovascular.

phase 1 HMG-CoA reductase inhibitor and cholesterol absorption inhibitor HMG-CoA reductase and Niemann-Pick C1-Like 1 (NPC1L1) Cardiovascular Small molecule

Target snapshot

Atrovastatin and Ezetimibe combination therapy (Atrovastatin and Ezetimibe combination therapy) — Chong Kun Dang Pharmaceutical. Inhibits HMG-CoA reductase and inhibits cholesterol absorption

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atrovastatin and Ezetimibe combination therapy TARGET	Atrovastatin and Ezetimibe combination therapy	Chong Kun Dang Pharmaceutical	phase 1	HMG-CoA reductase inhibitor and cholesterol absorption inhibitor	HMG-CoA reductase and Niemann-Pick C1-Like 1 (NPC1L1)
statins, ezetimibe	statins, ezetimibe	Korea University Anam Hospital	marketed	HMG-CoA reductase inhibitor and cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HMG-CoA reductase inhibitor and cholesterol absorption inhibitor class)

1. Chong Kun Dang Pharmaceutical · 1 drug in this class